Safety and Efficacy of Adding Azarga Adjunctive to Prostaglandin Therapy

Inclusion Criteria:

• Must be 18 years of age or older.
• Must have a clinical diagnosis of ocular hypertension, primary open-angle or pigment dispersion glaucoma in both eyes.
• At Screening/baseline visit, must have an IOP of ≥ 20 millimeters mercury (mm Hg) in at least one eye and ≤ 35 mm Hg in both eyes treated with prostaglandin monotherapy.
• In any eye not qualifying as a study eye, the intraocular pressure should be able to be controlled on no pharmacologic therapy or on prostaglandin monotherapy alone.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Known medical history of allergy, hypersensitivity or poor tolerance to any component of Azarga® that is deemed clinically significant in the opinion of the investigator.
• Corneal dystrophies in either eye
• Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.
• Bronchial asthma or a history of bronchial asthma, bronchial hyper reactivity, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker.
• History of severe allergic rhinitis.
• A condition, which in the opinion of the principal investigator, would interfere with optimal participation in the study, or which would present a special risk to the subject.
• Participation in any other investigational study within 30 days prior to the screening/baseline visit.
• Other protocol-defined exclusion criteria may apply.